Skip to main content
. 2017 Jan 18;37(3):637–647. doi: 10.1523/JNEUROSCI.2110-16.2016

Figure 1.

Figure 1.

TREM2 deficiency reduces amyloid pathology early but exacerbates it late in disease progression. a, b, The 6E10-immunoreactive area was assessed in the cortex of APPPS1;Trem2+/+ and APPPS1;Trem2−/− mice at 2 months of age (a) and 8 months of age (b). c, d, Thioflavin S+ plaque number per square millimeter was assessed in APPPS1;Trem2+/+ and APPPS1;Trem2−/− mice at 2 months of age (c) and 8 months of age (d). e, There was a significant reduction in 6E10 immunoreactive area in the cortex of 2-month-old TREM2-deficient mice (WT, n = 3 M/2 F; KO, n = 3 M/2 F) and a significant increase in 6E10 immunoreactive area in the cortex of 8-month-old TREM2-deficient mice compared with controls (WT, n = 4 M/2 F; KO, n = 4 M/3 F). f, There was a trend toward a reduction in the density of ThioS+ plaque number in the cortex of 2-month-old APPPS1;Trem2−/− cortex compared with APPPS1;Trem2+/+ controls (WT, n = 4 M/2 F; KO, n = 3 M/3 F), but no significant difference in ThioS+ plaque density in the cortex of 8-month-old TREM2-deficient mice (WT, n = 4 M/2 F; KO, n = 5 M/3 F). g, Analysis of 6E10+ plaque size revealed no significant differences in 2-month-old TREM2-deficient mice (WT, n = 3M/2F; KO, n = 3M/3F), but a significant increase in 8-month-old TREM2-deficient mice compared with controls (WT, n = 4 M/2 F; KO, n = 4 M/2 F). h, Transcript levels of human APP were assessed in 2-month-old mice (WT, n = 4 M/2 F; KO, n = 3 M/3 F) and 8-month-old mice (WT, n = 4 M/2 F; KO, n = 3 M/3 F). i, Western blots were used to examine the protein levels of human APP using 6E10 in cortical lysates from 2-month-old mice (WT, n = 3 M/2 F; KO, n = 3M/2F) and 8-month-old mice (WT, n = 3 M/2 F; KO, n = 3 M/2 F) mice. j, APP protein levels were normalized to actin and the fold change expressed to the WT for each age. ns, Not significant; *p < 0.05; **p < 0.01.